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Abstract 
Endocrine therapy for oestrogen receptor-positive (ER+) breast cancer (BC) is arguably the 
most successful targeted cancer therapy to date. Nevertheless, resistance to endocrine therapy 
still occurs in a significant proportion of patients, limiting its clinical utility. ER+ or luminal 
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BC, which represents around three quarters of all breast malignancies, are biologically 
heterogeneous with no distinct, clinically defined sub-classes able to predict the benefit of 
endocrine therapy in early settings. To improve patient outcomes, there is a clear need for 
improved understanding of the biology of the luminal BC, with subsequent translation into 
more effective methods of diagnosis to identify potential predictive biomarkers for endocrine 
therapy. This review summarises current knowledge of factors predictive of benefit of 
endocrine therapy, and discusses why molecular classification systems of BC have yet to be 
translated into the clinic. 
 
Keywords: breast cancer, luminal, endocrine therapy response, resistance, oestrogen receptor, 
predictive biomarker 
 
Introduction 
Oestrogen receptor (ER) is the driving transcription factor in up to three-quarters of all BC 
and its protein expression by immunohistochemistry classifies patients as either having ER+ 
or ER-negative (ER-) disease. Endocrine therapy is one of the most effective and well-
established targeted anti-cancer treatments for ER+ BC. However, despite its undisputed 
efficacy, up to one third of patients will relapse after treatment for early stage disease, whilst 
in the advanced setting, all will eventually progress and become resistant [1]. It is therefore 
desirable to be able to predict, at an early stage of treatment, which ER+ patients will benefit 
from endocrine therapy, and which are likely to develop resistance, so that alternative or 
additional therapies can be offered to prevent relapse and reduce BC specific mortality. The 
identification of biomarkers to predict endocrine therapy benefit in addition to ER status is 
therefore of crucial importance in stratifying ER+ patients for targeted therapy. During the 
past two decades, the molecular era has promised much with respect to prediction of benefit 
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from endocrine therapy in early BC, but clinicians remain unable to predict which of their 
patients will benefit from endocrine therapy.  
ER and progesterone receptor (PR) measurements are currently used for both clinical 
diagnosis to classify BC patients and as a guide to endocrine therapy [2]. Although the 
absence of ER expression is well known predictor of lack of hormonal therapy effect, the 
response of ER+ tumours to hormone therapy is heterogeneous. The role of PR measurement 
to predict benefit to endocrine therapy remains controversial. Some studies suggests its 
measurement lacks clinical value in BC management [3], while other reports considered that 
PR expression is a positive prognostic factor in ER+ BC [4, 5]. There is therefore a clear 
unmet clinical need for further biomarkers, beyond ER and PR, to help in predicting the 
benefit from endocrine therapy. 
Global gene expression profiling (GEP) studies of BC have identified a distinct molecular 
subtype called ‘luminal-like’. The current accepted molecular classification of luminal 
subtype divides them into two subgroups: luminal A and luminal B [6]. Luminal B disease 
demonstrates increased expression of proliferation-related genes which make it more 
aggressive in its clinical behaviour [7]. This subtype has a higher recurrence rate and lower 
survival rates after relapse [8], and is considered as a more aggressive subtype of ER+ 
disease, while luminal-A disease tends to result in better clinical outcomes [7]. However, 
such molecular classification is currently not routinely used in the clinic to guide endocrine 
therapy. 
Thus, there remains an urgent need to identify biomarkers, singularly or in combination, and 
clinically relevant subclasses within ER+ BC to refine classification of luminal tumours, 
particularly with a view to predicting the benefit from the endocrine therapy in early BC. In 
this article, we provide a comprehensive review of the current modalities with potential 
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applicability in predicting benefit from endocrine therapy. The article focusses on why 
molecular classification systems have yet to be translated successfully into the clinic for this 
purpose, and how the field can move forward in order to improve patient outcomes. 
 
Endocrine therapy 
Endocrine therapy is a well-established standard treatment for ER+ BC patients. Classes of 
endocrine therapy include selective ER modulators (SERMs) (e.g. tamoxifen), aromatase 
inhibitors (AI) (e.g. anastrozole, exemestane and letrozole) and selective ER down-regulators 
(SERDs) (e.g. fulvestrant). The key clinical questions for those with ER+ BC are 1) which 
endocrine therapy should be offered and 2) what is the role of biomarkers in selecting 
patients for the most effective therapy option?  
 
Mechanisms of action 
Current endocrine therapy works either by blocking or lowering the action of ER, or 
inhibiting peripheral synthesis of oestrogen from its precursors in the circulation. Tamoxifen, 
a SERM, is non-steroidal synthetic agent that exhibits tissue-specific ER agonist or 
antagonist activity. The mechanism of action of tamoxifen involves a competitive inhibition 
of oestrogen binding to the ER via its ligand-binding domain. This induces a conformational 
change in the nuclear receptor. In ER+ breast tumours, binding of tamoxifen to the ER results 
in inhibition of oestrogen dependent gene transcription, cell proliferation and tumour growth 
[1]. Tamoxifen causes apoptosis and cell cycle arrest in G0/G1 phase via modulating growth 
factors. However, tamoxifen also exerts an agonist effect on the endometrium, thus 
increasing the risk of developing endometrial cancer as a side effect of BC treatment [1]. 
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AIs reduce oestrogen levels by blocking the peripheral conversion of androgen to oestrogens 
catalysed by the aromatase enzyme. They are classified by their mechanisms of action into 
two types: steroidal agents such as exemestane, which irreversibly inactivates the enzyme, 
and non-steroidal such as anastrozole and letrozole, which inhibit aromatase through 
reversible binding [9]. AIs are recommended above tamoxifen for postmenopausal women 
with ER+ BC [10]. 
Fulvestrant, a SERD, is known as a “pure” anti-oestrogen as it does not have any agonist 
activity in other tissue contexts. It binds competitively to ER, inhibits its dimerisation and 
ultimately results in downregulation of ER expression [11]. Although fulvestrant is not 
currently approved by the National Institute for Health and Excellent Care (NICE) in the UK 
for the treatment of ER+ BC, it is widely used in the advanced setting and is approved by the 
US Food and Drug Administration (FDA) and European Medicines Agency (EMA) [12, 13]. 
 
Success 
Tamoxifen is considered the gold standard endocrine therapy for premenopausal women with 
early and advanced ER+ BC, and post-menopausal women who have contra-indications to 
AIs [10, 14]. The 2011 meta-analyses from the Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) showed that, for ER+ patients, 5 years treatment with tamoxifen reduced 
the risk of BC recurrence and mortality by 39% and 30%, respectively [15]. A further 
reduction of the recurrence risk in ER+ BC can be achieved by extending the duration of 
tamoxifen treatment to 10 years [16]. However, whilst there has been a significant fall in 
mortality rates with the use of tamoxifen, a third of patients experience resistance to 
tamoxifen. Resistance is classified as either primary (relapse within the first 2 years of 
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adjuvant endocrine therapy) or secondary (relapse after 2 years on endocrine therapy, or 
within 12 months of completing adjuvant endocrine therapy) [17]. 
In postmenopausal women with ER+ BC, treatment with AIs is marginally superior to 
tamoxifen in efficacy both in terms of the risk of recurrence and overall survival [10, 18]. 
Recently, it has been reported that in premenopausal women with ER+ BC, clinical outcomes 
for patients with high recurrence risk may be improved by treatment with AIs and ovarian 
function suppression compared to tamoxifen alone [19].  
 
Cyclin-dependent kinases 4 and 6 inhibitors 
Cyclin-dependent kinases 4 and 6 (CDK4/6) are important drivers of the cell cycle and are 
required for the initiation and progression of various tumours [20, 21]. Inhibitors of CDK4/6 
lead to cell cycle arrest in the G1 phase by preventing phosphorylation of retinoblastoma 
protein, and thereby prevent tumour progression [22]. Currently, there are three selective 
inhibitors of CDK4/6 (palbociclib, abemaciclib and ribociclib) have been tested in clinical 
BC trials. Palbociclib has been approved by the FDA and EMA, in combination with an AI as 
endocrine based therapy in postmenopausal women with ER+/HER2-negative advanced or 
metastatic BC [23, 24]. Ribociclib has also been approved by the FDA, as initial treatment for 
postmenopausal women with advanced ER+/HER2-negative BC [24].  
In the near future, the role of CDK4/6 inhibitors is likely to expand into the setting of early 
BC. For example, abemaciclib is currently being explored in combination with standard 
endocrine therapy for patients at higher risk of relapse [25]. 
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ER and PR measurement 
The determination of ER protein expression has been used in the clinic for over 30 years to 
identify patients likely to benefit from endocrine therapy. Despite this, ER positivity is 
insufficient to predict whether an individual patient with early breast cancer is likely to 
experience disease relapse.  
In addition to ER, there is some additional predictive benefit in measuring  progesterone 
receptor (PR) expression, as recommended by the Royal College of Pathologists [2]. 
Immunohistochemistry (IHC) remains the most commonly used diagnostic technique for 
determination of ER and PR status as it is relatively quick, cheap and can be performed on 
formalin-fixed paraffin embedded (FFPE) tissue. Although the St. Gallen Guidelines 
recommended IHC for use in clinical practice in 2013 [14], there is no gold standard assay 
available for determination of ER and PR status by IHC with regard to the prediction of 
benefit from endocrine therapy. Until the recent decade, ER positivity was defined in routine 
clinical practice using a cut-off value for ER nuclear staining of 10%. By this criterion, 
patients with ≥ 10% nuclear staining of ER were deemed eligible for endocrine therapy [26]. 
The American Society of Clinical Oncology (ASCO) Reported Guidelines for ER and PR 
IHC assays was an attempt to make the benefit of endocrine therapy available to the widest 
range of patients. ASCO recommends 1% as a universal cut-off point to distinguish between 
ER positivity and negativity to help determine likelihood of patients responding to endocrine 
therapy. Thus, they considered “1% or more of cells staining for ER” as the cut-off for a 
specimen to be considered positive. Tumours with less than 1% of cells staining for ER are 
considered ER negative based on data that patients with such tumours do not receive 
meaningful benefit from endocrine therapy [27]. However, lowering the threshold for ER 
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positivity increases the proportion of patients in whom endocrine therapy is indicated. This 
has raised uncomfortable questions about the low ER+ (1-9%) tumours.  
 
Subsequent studies have confirmed the suspicion that a significant proportion of these low-
ER+ are in fact non-luminal tumours. It is therefore suggested that the most expeditious 
therapeutic approach may be to use both endocrine therapy and chemotherapy in this subset 
of patients [28, 29]. It is reported that patients with low ER tumours (1–9%), in contrast to 
those with ER+ ≥10%,  have clinicopathological characteristics more similar to those of the 
ER- negative tumours and did not appear to benefit from endocrine therapy [26]. A 
retrospective study of early breast cancer including patients with HER2-negative and low 
hormone (ER and PR) receptor expression tumours reported no clear effect on survival 
outcomes with the addition of endocrine therapy for patients with low ER/PR (1-9%) [30]. A 
further study supported this finding in early breast cancer, reporting that this subgroup 
behaves clinically like triple-negative BC in terms of pathological complete response and 
survival outcomes [31].  
 
All of these results suggest that BC with low ER expression 1-9% and those with ≤ 1% of ER 
may have similar molecular features and clinical prognoses, but differ in terms of efficacy of 
endocrine therapy compared to patients who have tumours with ≥10% of cells staining 
positive for ER. 
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Whilst the measurement of ER is useful as a predictive biomarker to determine the efficacy 
of endocrine therapy, the role of PR in predicting response to endocrine therapy for patients 
with ER+ tumours is controversial. Thus, while it has been reported that benefit from 
tamoxifen is similar between PR+ and PR- patients [32] and also that PR status does not 
affect the relative efficacy of AI over tamoxifen [33], other studies report that PR status is an 
independent predictive indicator of endocrine therapy response and is associated with better 
overall survival and less relapse [34, 35]. A recent mechanistic study demonstrated that, in 
the presence of progesterone, PR guides ER to genomic binding sites associated with more 
favourable clinical outcomes [36]. Therefore PR positivity can be considered a biomarker of 
good response to endocrine therapy. Positive PR expression could, in future, be utilised to 
augment endocrine therapy response by the addition of progesterone to an ER-antagonist. In 
the meantime, there is still a need to find biomarkers beyond ER and PR status to predict 
endocrine therapy benefit, due to the complex biology and heterogeneity of luminal BC. 
 
ER-negative BC and benefit from endocrine therapy 
Breast tumours that are ER negative but PR+ by current criteria are difficult to interpret and 
present a clinical challenge. Typically, patients with ER-/PR+ tumours will be given 
endocrine therapy. Although some studies do suggest the existence of a PR-positive class 
within ER-negative tumours, in up to 2–8% of cases, and that patients with these tumours 
may benefit from endocrine therapy [34, 37-39], there is controversy over whether the ER-
/PR+ phenotype is a real phenomenon. Several recent studies including those from our group 
have indicated that ER-/PR+ phenotype represents a technical failure, resulting from either 
false-negative ER or false-positive PR result, at least in the majority of cases [27, 40-42].  
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In routine practice we have seen rare cases showing ER-/PR+ phenotype despite repeat 
staining of both markers. However, the frequency is less than 1%, with 4 cases seen in 9000 
breast cancers (unpublished data). As expected these tumours exhibit more aggressive 
behaviour than the double positive tumours (ER+/PR+) [37, 39, 43]; however, the benefit of 
endocrine therapy in patients with these rare tumours featuring a genuine ER-/PR+ phenotype 
remains to be confirmed [15, 27, 44, 45]. The very low incidence of the tumours is likely to 
limit the ability to evaluate the benefit form endocrine therapy in clinical trials. 
 
Gene expression profiling 
Gene expression profiling (GEP) studies over the past two decades have led to the molecular 
classification of BC into at least four subtypes. Computational methods have been used to 
subclassify BC based on gene expression pattern across clinical samples. The first study 
identified four subtypes based on expression of ESR1 (the gene encoding ER), ER-related 
genes and HER2. In this classification system, ER+ tumours comprise the largest class 
characterised by expression of not only ESR1 and ER-related genes, but also of low 
molecular weight cytokeratins and other genes characteristic of luminal epithelial cells. This 
intrinsic subtype was termed luminal class with no further sub-classification [46].  
A subsequent study interrogated GEP data obtained from 78 BC cases and seven non-
malignant breast samples, and further defined the intrinsic molecular subtypes of BC. This 
study classified luminal tumours into 3 subclasses including luminal-A, B and C. Luminal-B 
and C were associated with poor prognosis and outcomes compared to luminal-A, which had 
the highest expression of ER and ER-regulated genes. In contrast to luminal-A and B, 
luminal-C shared a high expression of genes with HER2 and basal-like subtypes, but with an 
unknown function [47].  
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Subsequent study by the same investigators using hierarchical clustering based on patterns of 
expression of 534 “intrinsic” genes failed to robustly identify luminal-C, and it subdivided 
luminal-like BC into luminal-A and luminal-B subtypes. Thus, some of the genes that 
previously clustered in the luminal-C subtype were clustered in the luminal-B and basal-like 
[48]. Classification of luminal BC differs between studies, most likely because of the 
identification and use of distinct intrinsic gene sets for cluster analysis. Most studies using 
GEP support the sub-classification of luminal tumours into luminal-A and B [6]. 
Although some luminal-B tumours have a similar signature to the HER2+ subtype, they are 
discriminated mainly by proliferation-related genes such as MKI67, CCNB1A and MYBL2. 
Luminal-A disease is a low proliferation phenotype associated with good prognosis and 
outcome, whereas the proliferative phenotype luminal-B is associated with worse clinical 
outcome [49]. Luminal-B tumours, though ER+, have a distinct molecular phenotype from 
the good-prognosis luminal-A subtype. Indeed, luminal-B tumours share many molecular 
features with ER-negative subtypes. Furthermore, the luminal-B subtype is defined by the 
expression of genes associated with endocrine therapy resistance such as CCNB1, MKI67, 
MYBL2, FGFR1 and ZNF703 [49]. However, classification of BC into luminal-A or B does 
not differentiate tumours according to endocrine therapy response and has not been 
incorporated into routine clinical practice.  
 
Multigene expression signatures 
Multigene signatures can be valuable as prognostic tools with regards to recurrence and the 
stratification of risk, but so far studies have not validated their value in predicting benefit 
from endocrine therapy. Additionally, most of these gene signatures are focused on 
association with outcome following adjuvant treatment with endocrine therapy with or 
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without chemotherapy.  Clinically, they have found useful application as biomarkers to pick 
out patients at high risk of relapse who would benefit most from the addition of 
chemotherapy prior to their endocrine treatment. However, they have not yet found a role in 
predicting benefit from endocrine therapy itself.  
It is important to investigate the value of multigene signatures in terms of predicting benefit 
from endocrine treatment, as this may also guide clinical decision making. Table 1 
summarises these multigene assays and recommendations for their use in ER+ BC.  
Improving upon the current panel of two biomarkers (ER and PR expression) to predict 
endocrine therapy benefit may in future identify patients who could be spared endocrine 
therapy and its associated side effects. Alternatively, better biomarkers could be used to 
identify patients who would benefit from alternative approaches such as CDK4/6 or MTOR 
inhibition, either alone or in combination with current endocrine therapy. 
Specific multigene signatures will now be discussed, with particular reference to their 
potential utility as predictors of benefit from endocrine therapy. 
 
PAM50 Prosigna 
The PAM50 Prosigna assay was developed to classify breast tumours into one of four 
intrinsic subtypes (Luminal-A, Luminal-B, HER2-enriched, and Basal-like), based on the 
expression measurement of 50 genes [50], which were first described in early GEP 
microarray studies [46-48]. This assay is performed on RNA isolated from FFPE breast 
tumour tissue and generates a risk of recurrence (ROR) score by weighting the molecular 
subtype correlations, pathologic tumour size and a subset of proliferation genes [50, 51]. 
PAM50 ROR score and intrinsic subtype can identify clinically relevant prognostic 
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subgroups of patient with a limited risk of metastasis after endocrine treatment only, for 
whom chemotherapy can be spared [52]. Additionally, another study reported that PAM50 
ROR provided significant additional prognostic information with respect to late distant 
recurrence (DR)-free survival compared with clinicopathological risk factors [53]. The 
ASCO guidelines recommend that this assay may be used for patient with ER/PR+, HER2-
negative (node-negative) early stage BC, in conjunction with other clinicopathologic 
variables, for predicting outcome and aiding decisions on adjuvant systemic chemotherapy 
[54]. 
PAM50 can potentially be utilised as a tool to determine whether extended endocrine therapy 
is required (beyond 5 years), although the assay has not yet been validated for this purpose. 
However, PAM50 lacks the ability to predict benefit from endocrine therapy as a first line 
treatment in early ER+ BC. Moreover, despite the fact that studies have confirmed that the 
PAM50 score can be used to determine which patients carry a high risk of late DR, this 
ability is more prognostic than predictive. 
 
Oncotype DX 
The Oncotype DX recurrence score (RS) is based on measuring the mRNA expression levels 
of 16 cancer related-genes and 5 housekeeping genes from FFPE tissue using the real-time 
qRT-PCR. This assay was developed for patients with ER+ lymph-node negative BC treated 
with tamoxifen to predict the risk of DR. The RS classifies patients into three groups: low, 
intermediate or high risk [55, 56]. Several reports have shown that the RS assay not only 
quantifies the likelihood of BC recurrence in ER+ patients, but also predicts the magnitude of 
chemotherapy benefit; thus low-risk patients derive minimal, if any, benefit from 
chemotherapy, while high-risk patients require more aggressive regimens [55, 57, 58]. 
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Despite the clinical validation of Oncotype DX, there remain questions as to whether this 
assay provides more independent prognostic information than can be gained from 
immunohistochemical assay of known markers such as ER, PR, HER2 and Ki67 (see later 
section on IHC4 score)  [59]. Thus there may be a simpler and cheaper way of obtaining the 
same prognostic information.  However, in favour of Oncotype DX, it is argued that 
immunohistochemical determination of Ki67 lacks standardisation among laboratories and 
there is a lack of quality assurance programmes. PAM50 ROR, in comparison to the 
Oncotype DX RS, was found to be a more useful prognostic assay for predicting the risk of 
DR after endocrine treatment in ER+ patients, with better differentiation of intermediate- and 
higher-risk groups [60]. The Oncotype DX assay can be useful in predicting the benefit from 
chemotherapy, but is not currently helpful in the clinical setting for predicting the benefit 
from endocrine therapy for early stage ER+ BC. The St. Gallen Group and ASCO guidelines 
recommend Oncotype DX RS for newly diagnosed BC patients with ER+/HER2-negative to 
determine prognosis and aiding decision of chemotherapy [14, 54]. 
MammaPrint 
The MammaPrint assay measures the expression of 70 genes involved in metastasis, 
proliferation, tumour stroma and invasion in BC, irrespective of ER status. This assay is a 
gene microarray-based prognostic score that stratifies patients into low-risk or high-risk 
groups and utilises fresh tissue that has had its RNA stabilised [61, 62]. Again, like the other 
gene tests, it is able to demonstrate that only the high-risk ER+ patients could potentially 
benefit from chemotherapy, whereas low-risk group could be spared this type of treatment 
[63, 64]. In ER+/PR+ (HER2-negative) patients, this assay was shown to be an independent 
prognostic marker and it may be integrated into a selection of strategies for patients who are 
candidates for more aggressive therapeutic approaches [65]. 
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The clinical utility of MammaPrint was recently confirmed in an international, prospective, 
randomised trail (MINDACT). The study found that women with early-stage BC, who were 
at a high clinicopathological risk and a low genomic risk according to MammaPrint for 
recurrence, could be spared chemotherapy [66]. The ASCO guidelines recommends the use 
of MammaPrint for patient with ER+/PR+, HER2-negative (node-negative) early stage BC, 
to guide decisions on adjuvant systemic chemotherapy [67], while St. Gallen group and 
EGTM do not differentiate between lymph node–negative and lymph node–positive disease 
[14, 68]. 
 
The requirement for fresh tissue has limited the clinical uptake of MammaPrint, as this is not 
always routinely available. The performance, validation and optimisation of MammaPrint 
using FFPE tissue remains to be validated [69]. 
 
Breast cancer index (BCI) 
The BCI is an algorithmic combination of a molecular grade index (MGI), consisting of the 
average expression of five cell cycle (proliferation)-associated genes (BUB1B, CENPA, 
NEK2, RACGAP1 and RRM2), the HOXB13:IL17BR (H:I) ratio which represents activation 
of the ER signalling pathway, and 4 housekeeping genes. The BCI assay uses RT-PCR and 
can be applied to FFPE tissues [70, 71]. The independent prognostic value of BCI in 
predicting the risk of distant metastasis in ER+/HER2- patients treated with endocrine 
therapy has been validated in several studies [72-74]. A recent study showed that BCI has 
more prognostic accuracy than Oncotype DX, indicating that additional subsets of patients 
with ER+ BC identified by BCI may be suitable candidates for extended endocrine therapy 
[75]. The St. Gallen Group and ASCO guidelines recommend that BCI may be used for 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
predicting outcome and aiding decision of chemotherapy for patients with ER+/HER2-
negative BC [14, 54]. 
 
EndoPredict (EP) 
The EndoPredict (EP) assay measures the gene expression profiles of eight BC-relevant 
genes (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP and STC2) and 3 
housekeeping genes in FFPE tissue sections by qRT-PCR in decentralised laboratories. The 
assay is useful for predicting the likelihood of DR in patients with ER+ HER2- BC treated 
with endocrine therapy [76]. The combination of EP with the two clinicopathological 
parameters, tumour size and nodal status, has resulted in an EPclin risk score, which can 
classify patients into low- and high-risk recurrence groups [77]. A study of 1702 
postmenopausal ER+/HER2-negative BC patients from two adjuvant phase III trials 
(ABCSG6, ABCSG8) showed that both EP and EPclin are useful prognostic tools for the 
identification of early and late DR following 5 years of adjuvant endocrine therapy [78]. The 
EPclin assay provides more prognostic information on late DR (10 years) after endocrine 
therapy than Oncotype DX, partly because of its integration with molecular data and the 
clinicopathological factors [79]. However, further validation for predicting late recurrence 
following endocrine therapy is required. 
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Table 1: Summary of predictive and prognostics models and recommendations of their use in ER+ 
BC. 
Assay No. of genes Sample 
type 
Platform Risk category Clinical 
utility 
Prediction of 
endocrine 
therapy 
efficacy 
 
Recommendations 
 
 
Multigene signatures: 
PAM50 
Prosigna 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncotype DX 
 
 
 
 
 
 
 
 
 
 
 
 
MammaPrint 
 
 
 
 
 
 
 
 
 
 
 
 
 
Breast cancer 
index (BCI) 
 
 
 
 
 
 
 
EndoPredict 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
 
 
FFPE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FFPE 
 
 
 
 
 
 
 
 
 
 
 
 
Fresh 
tissue 
/FFPE 
 
 
 
 
 
 
 
 
 
 
 
FFPE 
 
 
 
 
 
 
 
 
 
PCR-based 
PAM50 
signature on 
the 
NanoString 
platform 
 
 
 
 
 
 
 
 
 
 
RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
DNA 
microarray 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR 
 
 
 
 
 
 
 
 
 
Low, 
intermediate or 
high risk for 
DR 
 
 
 
 
 
 
 
 
 
 
 
 
Low, 
intermediate or 
high risk for 
DR 
 
 
 
 
 
 
 
 
 
Low or high 
risk for DR 
 
 
 
 
 
 
 
 
 
 
 
 
Low or high 
risk for DR 
 
 
 
 
 
 
 
 
Prognostic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prognostic/ 
predictive 
 
 
 
 
 
 
 
 
 
 
 
Prognostic 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prognostic 
 
 
 
 
 
 
 
 
 
No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No 
 
 
 
 
 
 
 
 
 
 
 
 
No 
 
 
 
 
 
 
 
 
 
 
 
 
 
No 
 
 
 
 
 
 
 
 
 
1. For patient with ER/PR+, HER2-negative 
(node-negative) early stage BC, in 
conjunction with other clinicopathologic 
variables, to guide decisions on adjuvant 
systemic chemotherapy [54]. 
2. St. Gallen group and EGTM do not 
differentiate between lymph node–negative 
and lymph node–positive disease [14, 68]. 
 
 
 
 
 
1. For patient with ER/PR+, HER2-negative 
(node-negative) early stage BC, to guide 
decisions on adjuvant systemic chemotherapy 
[54]. 
2. St. Gallen group and EGTM do not 
differentiate between lymph node–negative 
and lymph node–positive disease [14, 68]. 
 
 
 
 
1. For patient with ER/PR+, HER2-negative 
(node-negative) early stage BC, in 
conjunction with other clinicopathologic 
variables, to guide decisions on adjuvant 
systemic chemotherapy [67]. 
2. St. Gallen group and EGTM do not 
differentiate between lymph node–negative 
and lymph node–positive disease [14, 68]. 
 
 
 
1. ASOC and EGTM for patient with 
ER/PR+, HER2-negative (node-negative) 
early stage BC, to guide decisions on 
adjuvant systemic chemotherapy [54, 68]. 
2. St. Gallen group do not differentiate 
between lymph node–negative and lymph 
node–positive disease [14]. 
 
1. For patient with ER/PR+, HER2-negative 
(node-negative) early stage BC, to guide 
decisions on adjuvant systemic chemotherapy 
[54]. 
2. St. Gallen group and EGTM do not 
differentiate between lymph node–negative 
and lymph node–positive disease [14, 68]. 
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*FISH: Fluorescence in situ hybridization. 
 
 
 
 
 
(EP) 
 
 
11 FFPE RT-PCR Low or high 
risk for DR 
Prognostic 
 
No 
 
 
 
Single biomarkers 
 
 
ER 
 
 
 
 
 
 
 
PR 
 
 
 
 
 
 
HER2 
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ASCO [54], St. Gallen Group [14] and 
EGTM [68] recommend ER measurement on 
all newly diagnosed primary invasive BC. 
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all newly diagnosed primary invasive BC. 
 
 
 
ASCO [54], St. Gallen Group [14] and 
EGTM [68] recommend HER2 measurement 
to guide anti-HER2 therapy in patients with 
early or advanced BC. 
 
 
 
 
St. Gallen Group [14] and EGTM [68] 
recommend Ki-67 measurement in 
combination with established clinical and 
pathological factors for determining 
prognosis in early BC. 
ASCO do not recommend its use because lack 
of reproducibility and standardisation [54]. 
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IHC surrogates for molecular classification 
With the limited early application of the molecular classes identified using GEP in clinical 
practice, robust alternatives including IHC biomarkers have been adopted as a surrogate for 
molecular profiling and prognostic stratification of patients.  
Using standard IHC methods, BC can be divided into luminal, HER2-enriched and triple-
negative subtypes (using ER, PR and HER2). Means of distinguishing between luminal-A 
and B subtypes include  Ki67 [80] and PR expression to definine luminal-B subtype [5]. 
Although IHC is considered the standard assay for Ki67 determination, significant variation 
between centres in assessment of Ki67 expression continues to limit its use in clinical 
management of BC [81, 82]. As a consequence, the St Gallen International Expert Consensus 
(2013) defined luminal-BC subtypes using IHC as luminal-A (ER+, HER2-, <14% Ki-67 and 
≥20% PR), luminal-B, subdivided into luminal-B HER2-negative (ER+, HER2- and at least 
one of: Ki-67 ≥14% or PR negative or low), luminal-B HER2-positive (ER+, HER2+ 
regardless of Ki67 or PR) [14].  
In terms of benefit from endocrine therapy, the St Gallen consensus suggested that luminal-A 
should be treated at relapse with endocrine therapy as it is less responsive to chemotherapy, 
while luminal-B HER2-negative should be treated with endocrine therapy plus 
chemotherapy. However, luminal-A tumours could be treated with chemotherapy in addition 
to endocrine therapy based on risk assessment e.g. large tumour size or patient preference 
[14]. This demonstrates that there remains uncertainty regarding risk assessment and choice 
of therapy and more precise molecular classification of ER+ BC is required in order to better 
predict benefit from endocrine therapy. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
IHC4 Assay 
IHC4 is a prognostic tool that measures the immunohistochemical level of four key markers 
ER, PR, HER2 and Ki-67 to predict risk of recurrence for patients treated with endocrine 
therapy, illustrated in Fig. 1. The IHC4 assay is performed on FFPE tissue and a risk score for 
recurrence is calculated. The amount of prognostic information of this assay is similar to that 
provided by Oncotype DX, and has been validated in an independent data set [59]. The main 
limitation of the IHC4 assay remains the lack of standardised quantification of the 
biomarkers, particularly with respect to Ki67 [83]. Like the multigene assays, IHC4 is not 
able to predict which patients will benefit from endocrine therapy, nor pick out those patients 
with early BC who would benefit from a combination of endocrine therapy and other targeted 
treatments. 
  
Mammostrat 
Mammostrat is an IHC based assay that measures the levels of five biomarkers (P53, 
SLC7A5, NDRG1, CEACAM5 and HTF9C) to provide an assessment of features of tumour 
biology distinct from hormone receptor status, HER2, or proliferation. This assay applied to 
FFPE tissues of ER+ BC tamoxifen-treated patients is able to predict the relative risk of 
recurrence (high, moderate or low) [84] and has been subsequently validated [85-87]. In 
patients with ER+ HER2- tumours, this assay may be used for determining prognosis and 
guiding decision making with respect to the use of chemotherapy. There is no data as yet on 
the clinical utility of the Mammostat assay in predicting benefit from endocrine therapy. 
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 Nottingham Prognostic Index Plus (NPI+) 
NPI+ is based on the well-established clinicopathological variables used in the traditional 
NPI but has been refined to integrate tumour biology with these clinicopathological factors. 
Primary invasive breast carcinoma are initially classified into seven distinct molecular classes 
using a panel of 10 biomarkers (ER, PR, CK 5/6, CK7/8, EGFR, HER2, HER3, HER4, p53 
and Mucin 1) which constitutes three luminal classes characterised by high luminal Ck7/8 
and hormone receptor expression [88], the classification is shown in decision tree format in 
Fig. 2. Luminal-A and Luminal-B classes show high expression of CK7/8, ER, HER3 and 
HER4 but are separated by lower levels of PR expression in Luminal-B. Luminal-N class 
shows differential expression of HER3 and HER4. The classes are followed by a second 
stage of stratification to incorporate clinicopathological variables, resulting in distinct 
prognostic groups within each molecular class [88]. 
Using the NPI+ formulae, the NPI+ distinctive classes of BC achieved an improved patient 
outcome stratification compared to the traditional NPI. Recently, the reproducibility and 
prognostic value of this tool was validated in an independent cohort of primary BC [89], and 
was suggested to be a useful tool in predicting the risk of metastases in primary BC [90]. 
However, despite the utility of this assay, it has limited literature to determine its ability to 
predict benefit form endocrine therapy. 
 
Are the above discussed assays useful in predicting benefit from endocrine therapy? 
There is increasing concern that all the assays discussed above are not sufficient to predict 
which patients with early BC will benefit from endocrine therapy, as their prognostic values 
are in predicting risk of recurrence or metastases. Furthermore, despite the fact that IHC4 has 
clinical validity for selecting women with ER+ BC who might be spared extended endocrine 
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therapy, there remains a clinical need for further research to establish new biomarkers to 
predict the benefit of endocrine therapy in early stage ER+ BC.  
The side effects of prolonged endocrine therapy are not inconsiderable. Debilitating non-
agent specific side effects of endocrine therapy that impair quality of life include hot flushes, 
fatigue and myalgia. Additionally, there are potentially serious side effects including bone 
demineralisation and osteoporosis (with AIs), and life-threatening toxicities such as venous 
thromboembolism (with tamoxifen). A biomarker assay that could pick out people with BC 
that would not benefit from endocrine therapy could spare people these risks and improve 
quality of life. 
On the other hand, assays such as those discussed above can pick out patients at higher risk of 
relapse, who should therefore be given more intense treatment with chemotherapy. In the 
future, biomarkers of endocrine therapy benefit may also pick out those at higher risk who 
would benefit from combinations of endocrine therapy with other targeted therapies such as 
MTOR or CDK4/6 inhibitors. 
 
Conclusion and future directions 
At present, there are no biomarkers that can be used to reliably predict which patients will 
benefit from endocrine therapy. Prediction of benefit from endocrine therapy is important in 
order to treat only those that have a good chance to respond, and spare non-responders from 
the side effects of additional hormonal treatment.  
Despite the clear advancement in multigene signatures in molecular classification or risk 
stratification of BC, none of these assays have found clinical utility in assessing endocrine 
therapy benefit in early stage ER+ BC, prior to treatment. Future studies that aim to identify 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
new predictive biomarkers may integrate detailed clinicopathological and histopathological 
data from large cohorts with full clinical annotation and long-term follow-up, and use 
multivariate model testing to establish the independence of potential biomarkers in addition 
to ER and PR. 
To identify new molecular biomarkers predictive of benefit from endocrine therapy, a 
retrospective study could be conducted using clinically annotated gene expression data from 
large cohorts, comparing clinical outcome in those treated only with endocrine therapy. This 
could then be integrated with protein expression data to produce a combined multigene 
signature and IHC score specific for predicting benefit from endocrine therapy. 
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Figures legend: 
Figure 1: Illustration of IHC4 and the corresponding risk score that combines the IHC4 score and the 
clinical score providing prognostic information on the risk of DR. The IHC4 score is based on the 
assessment of four key proteins ER, PR, HER2 and Ki-67. The clinical score is based on the 
evaluation of clinical parameters such as nodal status, tumour size, age, grade and endocrine 
treatment.   
Figure 2: Illustration of NPI+ assay and the use of panel of biomarkers to classify BC into seven 
distinct molecular classes. 
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